Ethnic disparities and liver transplantation rates in hepatocellular carcinoma patients in the recent era: Results from the surveillance, epidemiology, and end results registry

Robert J. Wong, Pardha Devaki, Long Nguyen, Ramsey Cheung, Mindie H. Nguyen – 10 January 2014 – Hepatocellular carcinoma (HCC) is a leading cause of morbidity and mortality. After the implementation of the Model for End‐Stage Liver Disease system, rates of liver transplantation (LT) for HCC patients increased. However, it is not clear whether this trend has continued into recent times. Using the Surveillance, Epidemiology, and End Results registry (1998‐2010), we retrospectively analyzed trends for LT among HCC patients in 3 time periods: 1998‐2003, 2004‐2008, and 2009‐2010.

GATA4 loss in the septum transversum mesenchyme promotes liver fibrosis in mice

Irene Delgado, Manuel Carrasco, Elena Cano, Rita Carmona, Rocío García‐Carbonero, Luis M. Marín‐Gómez, Bernat Soria, Francisco Martín, David A. Cano, Ramón Muñoz‐Chápuli, Anabel Rojas – 10 January 2014 – The zinc finger transcription factor GATA4 controls specification and differentiation of multiple cell types during embryonic development. In mouse embryonic liver, Gata4 is expressed in the endodermal hepatic bud and in the adjacent mesenchyme of the septum transversum. Previous studies have shown that Gata4 inactivation impairs liver formation.

GATA4 loss in the septum transversum mesenchyme promotes liver fibrosis in mice

Irene Delgado, Manuel Carrasco, Elena Cano, Rita Carmona, Rocío García‐Carbonero, Luis M. Marín‐Gómez, Bernat Soria, Francisco Martín, David A. Cano, Ramón Muñoz‐Chápuli, Anabel Rojas – 10 January 2014 – The zinc finger transcription factor GATA4 controls specification and differentiation of multiple cell types during embryonic development. In mouse embryonic liver, Gata4 is expressed in the endodermal hepatic bud and in the adjacent mesenchyme of the septum transversum. Previous studies have shown that Gata4 inactivation impairs liver formation.

Written informed consent for living liver donor evaluation: Compliance with centers for medicare and medicaid services and organ procurement and transplantation network guidelines and alibi offers

Carrie Thiessen, Yunsoo A. Kim, Peter S. Yoo, Manuel Rodriguez‐Davalos, David Mulligan, Sanjay Kulkarni – 10 January 2014 – We examined written informed consent forms for living liver donor evaluations to determine whether they incorporated elements required by the Centers for Medicare and Medicaid Services (CMS) and suggested by the Organ Procurement and Transplantation Network (OPTN). We contacted each of the 41 US centers that performed at least 1 living donor liver transplant in 2011; 37 centers reported active living donor evaluation programs.

Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage

Yeon Seok Seo, Soo Young Park, Moon Young Kim, Ju Hyun Kim, Jun Yong Park, Hyung Joon Yim, Byoung Kuk Jang, Hong Soo Kim, Taeho Hahn, Byung Ik Kim, Jeong Heo, Hyonggin An, Won Young Tak, Soon Koo Baik, Kwang Hyub Han, Jae Seok Hwang, Sang Hoon Park, Mong Cho, Soon Ho Um – 10 January 2014 – Vasoactive drugs are recommended to be started as soon as possible in suspected variceal bleeding, even before diagnostic endoscopy. However, it is still unclear whether the therapeutic efficacies of the various vasoactive drugs used are comparable.

Liver biopsy–related infection in liver transplant recipients: A current matter of concern?

Cristina López Sánchez, Oscar Len, Joan Gavalda, Itxarone Bilbao, Lluis Castells, Maria Arantzazu Gelabert, Helena Allende, Albert Pahissa – 7 January 2014 – Data from published studies regarding risk factors for liver biopsy (LB)–related infectious complications in liver transplant recipients are inconsistent. We carried out a retrospective cohort study analyzing consecutive LBs for orthotopic liver transplant patients at a tertiary hospital (2001‐2011): there were 667 LB procedures (575 percutaneous procedures and 92 transjugular procedures) in 286 liver transplant recipients.

Insulin‐like growth factor 2 mRNA‐binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma

Tony Gutschner, Monika Hämmerle, Nikolaos Pazaitis, Nadine Bley, Evgenij Fiskin, Hannah Uckelmann, Andreas Heim, Matthias Groβ, Nina Hofmann, Robert Geffers, Britta Skawran, Thomas Longerich, Kai Breuhahn, Peter Schirmacher, Britta Mühleck, Stefan Hüttelmaier, Sven Diederichs – 7 January 2014 – Hepatocarcinogenesis is a stepwise process. It involves several genetic and epigenetic alterations, e.g., loss of tumor suppressor gene expression (TP53, PTEN, RB) as well as activation of oncogenes (c‐MYC, MET, BRAF, RAS).

Subscribe to